Skip to main content

Emyria welcomes dosing of first patient in Phase 3 anxiety trial

Emyria Ltd (ASX:EMD) MD Michael Winlo tells Proactive the company has dosed its first patients in the pivotal Phase 3 clinical trial of lead drug candidate EMD-RX5. This marks an important milestone in the development of EMD-RX5 as the first potential over-the-counter (OTC) treatment for the symptoms of psychological distress.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.